A Study LY2228820 for Recurrent Ovarian Cancer

NCT01663857 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions

DRUG: LY2228820
DRUG: Carboplatin
DRUG: Placebo
DRUG: Gemcitabine

Sponsor

Eli Lilly and Company